Chemours Company (The)

As of June 30, 2026, Chemours Company (The) carries a market capitalization of 3.09B, placing it among publicly traded companies globally. Its enterprise value stands at 6.54B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Chemours Company (The)'s next confirmed earnings release is scheduled for November 2, 2026.

As of June 30, 2026, Chemours Company (The) has 150.46M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.53, and the price-to-book ratio stands at -63.01.

As of June 30, 2026, Chemours Company (The) trades at an EV/EBITDA multiple of 13.68 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.13 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 41.12 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 6.54B versus a market cap of 3.09B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Chemours Company (The) maintains a current ratio of 1.66, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -8,583.33, indicating conservative leverage, while an interest coverage ratio of 1.75 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -4.15, reflecting losses generated across the asset base. The company generates approximately 1.00M in revenue per employee across its workforce of 5,775.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.26 indicates how many times Chemours Company (The) sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Chemours Company (The) recorded 266.00M in income tax expense. The company reported a pretax loss of -39.00M and -304.00M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Chemours Company (The)'s stock has declined approximately 3.62% over the past 52 weeks. The 50-day moving average sits at 14.52, while the 200-day moving average is 18.43.

Over the twelve months ended June 30, 2026, Chemours Company (The) generated 5.80B in revenue and converted that into -304.00M in net income, yielding earnings per share of -2.01. EBITDA reached 478.00M, while operating income came in at -83.00M.

As of June 30, 2026, Chemours Company (The) holds 671.00M in cash and equivalents against 4.12B in total debt, resulting in a net debt position of 3.20B. Total book value stands at -49.00M, with working capital of 1.23B providing operational flexibility.

Chemours Company (The) produced 397.00M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -179.00M in capital expenditures, free cash flow totaled 218.00M - equivalent to 1.45 per share.

Over the twelve months ended June 30, 2026, Chemours Company (The) posted a gross margin of 15.30, reflecting its pricing power and cost economics. The operating margin of -1.43 and net profit margin of -5.24 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Chemours Company (The) paid dividends of 0.36 per share. The dividend payout ratio of -17.65 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Free cash flow yield stands at 7.02, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 11.34, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Chemours Company (The) shareholders.

As of June 30, 2026, Chemours Company (The) has an Altman Z-Score of 1.42, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.